Exact Sciences’ announced today its initial clinical validation data for its Profile for the Omission of Local Adjuvant Radiotherapy (POLAR).

According to a release, POLAR is the first genomic signature that is both prognostic for the risk of local-regional recurrence and predictive of radiotherapy benefit. It successfully predicted which patients would and would not benefit from local radiation therapy.

“Exact Sciences’ POLAR signature addresses a significant clinical need for those with early-stage, hormone receptor-positive breast cancer, identifying which patients may benefit from radiotherapy and which may not,” Exact Sciences Chief Medical Officer of Precision Oncology Rick Baehner, M.D., said in a statement.

There were a total of 623 patients in the analysis.